• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/85

Click to flip

85 Cards in this Set

  • Front
  • Back
  • 3rd side (hint)
Bendamustine
Treanda
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
F:IV
Indications: Lymphoma, CLL
Toxicities:
Myelosuppression
GI toxicity (vomiting)
Busulfan
Myleran
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
F:IV, PO
Indications: CML
Toxicities:
Myelosuppression
GI toxicity (nausea, vomiting, diarrhea)
Hepatotoxicity (veno-occlusive disease)-high dose
CNS toxicity (seizure)-high dose
Misc:rapid and complete oral absorption
Carboplatin
Paraplatin
ALKYLATING AGENT
Platinum Complex
MOA: activated by aquation intracellularly (low Cl- concentration)-->react with DNA forming intrastand (favored) and interstrand cross-linked (adducts), N7 of guanine as the primary target, DNA adducts inhibit DNA replication and transcription leading to breaks and miscoding-->apoptosis
Indications: lung, lymphoma, ovarian
F: IV
Toxicities:
Myelosuppression- more severe
Other toxicities less severe than cisplatin
Misc: NOT cell cycle specific, NO aluminum needles or equipment preparing or administering all platinum-containing drugs, dose reduction for renal impairment
Chlorambucil
Leukeran
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
Indications: CLL
F: PO
Toxicities:
Myelosuppression
Secondary malignancy (leukemia)
Cisplatin
Platinol-AQ
ALKYLATING AGENT
Platinum Complex
MOA: activated by aquation intracellularly (low Cl- concentration)-->react with DNA forming intrastand (favored) and interstrand cross-linked (adducts), N7 of guanine as the primary target, DNA adducts inhibit DNA replication and transcription leading to breaks and miscoding-->apoptosis
Indications:ovarian, testicular, lung, melanoma
F:IV
Toxicities:
Nephrotoxicity, alleviated by chloride diuresis and amifostine (ETHYOL®)
Neurotoxicity (peripheral neuropathy)
Ototoxicity
GI toxicity (severe vomiting and nausea), alleviated by aprepritant(EMEND®), dexamethasone and 5-HT3 antagonists
Myelosuppression (mild to moderate)- mild compared to other agents and other toxicities
Misc: NOT cell cycle specific, NO aluminum needles or equipment preparing or administering all platinum-containing drugs, mainly urine excretion
Cyclophosphamide
Cytoxan, Neosar
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
Indications: Breast, ALL, CLL, Lung, Lymphoma
F: PO, IV
Toxicities:
Myelosuppression (severe)
GI toxicity (nausea, vomiting)
Hemorrhagic cystitis-->due to accumulation of acrelein in the bladder , counteracted by mesna and diuresis (Mesna congregates w/acrelein--> reduce bladder toxicity)
Cardiotoxicity (high doses)
Secondary malignancy
Misc: Phosphoramide mustard--> active metabolite--> anti-tumor effects

Dacarbazine
DTIC-Dome
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
F:IV
Indications: Lymphoma
Toxicities:
Myelosuppression
GI toxicity (nausea, vomiting)
Ifosfamide
Ifex
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
Indications: Lymphoma
F: IV
Toxicities:
myelosuppression (more severe than CyPhos)
hemorrhagic cystitis, alleviated by mesna and diuresis
CNS toxicity (hallucination, coma)
GI toxicity (nausea, vomiting)
Misc: Much slower activation in the body, More lipophilic crosses BBB, metabolized by CYP3A4 to active form
Mechlorethamine
Mustargen
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
Indications: Lymphoma
F: IV
Toxicities:
Myelosuppression
GI toxicity (nausea, vomiting)
Misc: rapid iv injection (very unstable), chemical degradation (hydrolysis, deamination) in water and body fluids within minutes
Oxaliplatin
Eloxatin
ALKYLATING AGENT
Platinum Complex
MOA: activated by aquation intracellularly (low Cl- concentration)-->react with DNA forming intrastand (favored) and interstrand cross-linked (adducts), N7 of guanine as the primary target, DNA adducts inhibit DNA replication and transcription leading to breaks and miscoding-->apoptosis
Indications: colorectal, gastric
F: IV
Toxicities:
Peripheral neuropathy- most severe
GI toxicity (diarrhea, stomatitis, nausea, vomiting)
myelosuppression (mild)
Misc: NOT cell cycle specific, NO aluminum needles or equipment preparing or administering all platinum-containing drugs, DON’T use any chloride -containing solutions to reconstitute
Procarbazine
Matulane
ALKYLATING AGENT
Nitrogen Mustard
MOA: Cytotoxic due to alkylation of DNA (neuclophilic attack of unstable aziridine ring by electron donor). N7 of guanine as the key target, causing interstrand cross-linkage of DNA chains.
F: PO
Indication: Lymphoma
Toxicities:
Myelosuppression
GI toxicity (N/V)
Secondary malignancy
Misc: rapid and complete oral absorption
5-Fluorouracil
5-FU, Adrucil, Efudex
ANTI-METABOLITE AGENT
Pyrimidine Antagonists
MOA: incorporated into both DNA and RNA, blocks thymidylate synthesis (major) by inhibiting thymidylate synthase
F:IV
Indications: colorectal, breast
Toxicities:
Myelosuppression-major
GI toxicity (nausea, vomiting, stomatitis, diarrhea)
Hand-foot syndrome (palmar-plantar erythrodysesthesia)
Misc: co-administration of leucovorin to enhance efficacy
Azacitidine
Vidaza
ANTI-METABOLITE AGENT
Pyrimidine Antagonists
MOA: Incorporates into DNA and inhibits methyltransferase, causing demethylation in DNA
Indications: AML
F: IV or SQ
Toxicities:
Myelosuppression
Renal toxicity
GI toxicity
6-Mercaptopurine
Purinethol
ANTI-METABOLITE AGENT
Purine Analog
MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA
Indication:ALL
F: PO
Toxicities:
Myelosuppression- dose limiting
Hepatotoxicity
GI toxicity (nausea, vomiting, mucositis, stomatitis)
Hyperuricemia, alleviated by allopurinol which inhibits xanthine oxidase to reduce the accumulation of uric acid , dose reduction by 75%
Misc: first pass metabolism by xanthine oxidase (to uric acid), dose reduction for renal impairment
Capecitabine
Xeloda
ANTI-METABOLITE AGENT
Pyrimidine Antagonists
MOA: (Prodrug of 5-FU) incorporated into both DNA and RNA, blocks thymidylate synthesis (major) by inhibiting thymidylate synthase
Indications: colorectal, breast
F: PO
Toxicities:
GI toxicity (diarrhea, vomiting, nausea)- most severe b/c oral
Hand-foot syndrome
Myelosuppression
Misc: dose reduction for renal impairment, Tumor specificity due to due high expression of thymidine phosphorylase in tumors and not in normal tissue= advantage over 5-FU
Cladribine
Leustatin
ANTI-METABOLITE AGENT
Purine Analog
MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA
Indication: CLL, lymphoma
F: IV
Toxicities:
Myelosuppression
GI toxicity (nausea, vomiting)
CNS toxicity (fever, chills)
Renal toxicity
Clofarabine
Clolar
ANTI-METABOLITE AGENT
Purine Analog
MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA
Indications: ALL
F:IV
Toxicities:
Myelosuppression
GI toxicity (nausea, vomiting, diarrhea)
Capillary leak syndrome/systemic inflammatory response syndrome (SIRS) (vascular tone loss and extravasation of plasma fluids and proteins)=pain
Hepatotoxicity
Cytarabine
Ara-C, Cytosar-U
ANTI-METABOLITE AGENT
Pyrimidine Antagonists
MOA: ara-CTP competes with dCTP for DNA incorporation, incorporated ara-CMP residues inhibit DNA polymerase, causes terminal differentiation of leukemic cells
Indications: AML, ALL
F: IV, IT
Toxicities:
Myelosuppression
GI toxicity (diarrhea, mucositis, nausea, vomiting)
CNS toxicity -high dose or intrathecal
Misc: susceptible to cytidine deaminase(short t1/2), DEPOCYT: intrathecal liposomal formulation for sustained release in CSF (less CNS toxicity)
Decitabine
Dacogen
ANTI-METABOLITE AGENT
Pyrimidine Antagonists
MOA: incorporates into DNA and inhibits methyltransferase, causing demethylation in DNA
Indication: AML
F: IV
Toxicities:
Myelosuppression
GI toxicity (nausea, vomiting, diarrhea)
Misc: rapid deamination
Fludarabine
Fludara
ANTI-METABOLITE AGENT
Purine Analog (arabinoside, adenosine-analog)
MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA
Indication: AML, CLL
F: IV, PO
Toxicities:
Autoimmune effects (hemolytic anemia)
Myelosuppression
GI toxicity (nausea, vomiting, diarrhea)
CNS toxicity (chills, blindness, coma, seizure)
Misc: dose reduction for renal impairment, adenosine deaminase- resistant due to presence of F at R1
Gemcitabine
Gemzar
ANTI-METABOLITE AGENT
Pyrimidine Antagonists
MOA: (tri-phosphorylated in vivo) dFdCTP competes with dCTP for DNA incorporation, inhibitor of DNA polymerase, dFdCDP inhibits ribonucleotide reductase
Indications:breast, lung, pancreas, ovarian
F: IV
Toxicities(mild compared to others):
Myelosuppression
GI toxicity (nausea, vomiting, diarrhea)
Hepatotoxicity
Misc:extended infusion time increases dFdCTP formation
Hydroxyurea
Hydrea
ANTI-METABOLITE AGENT
MOA: inhibits ribonucleotide reductase--> block biosynthesis of DNA
Indications: CML, Melanoma
F: PO
Toxicities:
Myelosuppression
Cutaneous vasculitic toxicity
Secondary malignancy (leukemia)
GI toxicity (stomatitis, diarrhea)
Misc: majority eliminated in the urine= dose reduction for renal impairment
Methotrexate
Folex, Rheumatrex
ANTI-METABOLITE AGENT
Folic Acid analog
MOA: dihydrofolate reductase ( DHFR ) inhibitor, MTX-PG is an inhibitor of DHFR, thymidylate synthase and de novo purine synthesis.
Indications: ALL, breast, lymphoma
F: IV
Toxicities:
Myelosuppression- dose limiting
GI toxicity (nausea, vomiting, stomatitis)
Nephrotoxicity (acute renal failure)
Misc: dose reduction for renal impairment, toxicities rescued by leucovorin (folinic acid, N 5-formyl FH4), a reduced folate coenzyme.
Nelarabine
Arranon
ANTI-METABOLITE AGENT
Purine Analog
MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA
Indications: ALL, lymphoma
F: IV
Toxicities:
Myelosuppression
Neurotoxicity (seizure, peripheral neuropathy)
GI toxicity (nausea, diarrhea, vomiting)
Misc: hepatic metabolism to form ara-G (active form)
Pemetrexed
Alimta
ANTI-METABOLITE AGENT
Folic Acid analog
MOA: dihydrofolate reductase ( DHFR ) inhibitor, more potent inhibitor of de novo purine synthesis (main mech)
Indications: lung, breast, pancreas, renal, head & neck
F:IV
Toxcities:
myelosuppression
GI toxicity (nausea, vomiting, stomatitis, diarrhea)
nephrotoxicty
dermotogical reactions
Misc: dose reduction for renal impairment,better transported into tumor cells than MTX
Pentostatin
Nipent
ANTI-METABOLITE AGENT
Purine Analog
MOA: inhibits de novo synthesis of purine bases and nucleotides, triphosphate derivatives incorporated into DNA
Indications: CLL, lymphoma
F: IV
Toxicities:
GI toxicity (N/V, diarrhea, stomatitis)
myelosuppression
Irinotecan
Camptosar, CPT-11
TOPOISOMERASE I INHIBITOR
Camptothecin Analog
MOA: The flat ring systems intercalate DNA at the site of cleavage, Bind and stabalize DNA-topoisomerase I “cleavable complex”, Inhibit the religation of single- stranded breaks in DNA, Cause irreversible DNA break during DNA replication, leading to apoptosis.
Indication: lung, colorectal, cervical, ovarian, gastric, brain
F:IV in polysorbate 80
Toxicities:
Diarrhea- most sig
Myelosuppression
Hypersensitivity reactions- caused by polysorbate 80 (pretreat w/dexamethasone and antihistamines)
Misc: metabolized by hepatic carboxylesterase to SN-38 (active), SN-38 is less hydrolyzed due to high plasma protein binding, dose reduction for hepatic impairment
Topotecan
Hycamtin
TOPOISOMERASE I INHIBITOR
Camptothecin Analog
MOA: The flat ring systems intercalate DNA at the site of cleavage, Bind and stabalize DNA-topoisomerase I “cleavable complex”, Inhibit the religation of single- stranded breaks in DNA, Cause irreversible DNA break during DNA replication, leading to apoptosis.
Indication: lung, ovarian
F:IV
Toxicities:
Myelosuppression
GI toxicity (diarrhea, nausea, vomiting)
Misc: 5 fused ring structure is signature for these compounds,spontaneous hydrolysis in whole blood forms less active metabolite= main metabolic pathway, dose reduction for renal impairment
Daunorubicin
Cerubidine
TOPOISOMERASE II INHIBITOR
Anthracycline
MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis
Indications: AML, ALL
F:IV
Toxicities:
Myelosuppression
Cardiotoxicity
Vesicant
GI toxicity (nausea, vomiting, stomatitis)
Misc: hepatic metabolism (active metabolite), red-colored urine, dose reduction for renal impairment
Doxorubicin
Adriamycin
TOPOISOMERASE II INHIBITOR
Anthracycline
MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis
Indications: breast, ALL, lung, lymphoma, ovarian
F: IV
Toxicities:
Myelosuppression- dose limiting
Cardiotoxicity (avoid combination with cyclophosphamide, other anthracyclines or herceptin)
Counteracted by concomitant use of dexrazoxane
Potent vesicant- causes pain in surrounding tissue
GI toxicity (nausea, vomiting, ulceration)
Secondary malignancy (AML)
Misc: dose reduction for hepatic impairment, rapid uptake in heart, kidney, lung, liver and spleen
Epirubicin
Ellence
TOPOISOMERASE II INHIBITOR
Anthracycline
MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis
Indications: BREAST, cervical, gastric
F: IV
Toxicities:
myelosuppression
cardiotoxicity
Vesicant
GI toxicities (nausea, vomiting, diarrhea)
Secondary malignancy (AML)
Misc: dose reduction for hepatic impairment, dose reduction for renal impairment, can cause red urine
Etoposide
VP-16, Vepesid
TOPOISOMERASE II INHIBITOR
Epipodophyllotoxin
MOA: forms a ternary complex with topoisomerase II and DNA causes double-stranded DNA breaks, most sensitive in cells during S and G2 phases
Indications: lung, lymphoma, testicular
F: IV
Toxicities:
Myelosuppression
GI toxicities (nausea, vomiting, diarrhea)
Hepatotoxicity
Hypersensitivity
Misc: dose reduction for renal impairment, polysorbate 80 as vehicle
Idarubicin
Idamycin PFS
TOPOISOMERASE II INHIBITOR
Anthracycline
MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis
Indications: AML, ALL
F: IV
Toxicities:
Myelosuppression
Cardiotoxicity
Vesicant
GI toxicity (nausea, vomiting, diarrhea)
Misc: dose reduction for hepatic impairment
Mitoxantrone
Novantrone
TOPOISOMERASE II INHIBITOR
Anthracycline
MOA: flat ring system intercalates directly with DNA, forms a complex with topoisomerase II and DNA, causing double-stranded DNA breaks, leading to apoptosis
Indications: prostate, lymphoma
F: IV
Toxicities:
Myelosuppression
Less cardiotoxicity and other toxicities than true anthracyclines
GI toxicity (nausea, vomiting, diarrhea)
Vesicant
secondary malignancy (AML)
Misc: Doesn’t have glycoside like other anthracyclines
Teniposide
Vumon
TOPOISOMERASE II INHIBITOR
Epipodophyllotoxin
MOA: forms a ternary complex with topoisomerase II and DNA causes double-stranded DNA breaks, most sensitive in cells during S and G2 phases
Indications: lymphoma, lung, pediatric ALL
F: IV
Toxicities:
Myelosuppression
Hypersensitivity reactions
GI toxicities (nausea, vomiting)
Misc: Cremophor EL as vehicle
Cabazitaxel
Jevtana
MICROTUBULE TARGETING AGENT
Docetaxel
Taxotere
MICROTUBULE TARGETING AGENT
Eribulin
Halaven
MICROTUBULE TARGETING AGENT
Estramustine
Emyct
MICROTUBULE TARGETING AGENT
Ixabepilone
Ixempra
MICROTUBULE TARGETING AGENT
Paclitaxel
Taxol
MICROTUBULE TARGETING AGENT
Paclitaxel-protein bound
Abraxane
MICROTUBULE TARGETING AGENT
Vinblastine
Velban
MICROTUBULE TARGETING AGENT
Vincristine
Oncovin, Vincasar
MICROTUBULE TARGETING AGENT
Vindesine
Eldisine
MICROTUBULE TARGETING AGENT
Vinorelbine
Navelbine
MICROTUBULE TARGETING AGENT
Erlotinib
Tarceva
TYROSINE KINASE INHIBITOR
Dasatinib
Sprycel
TYROSINE KINASE INHIBITOR
Gefitinib
Iressa
TYROSINE KINASE INHIBITOR
Imatinib
Gleevec
TYROSINE KINASE INHIBITOR
Lapatinib
Tykerb
TYROSINE KINASE INHIBITOR
Nilotinib
Tasigna
TYROSINE KINASE INHIBITOR
Vemurafenib
Zelboraf
TYROSINE KINASE INHIBITOR
Crizotinib
Xalkori
TYROSINE KINASE INHIBITOR
All-trans retinoic acid
Vesanoid, ATRA
DIFFERENTIATION AGENT
MOA: promotes the degradation of PML-RAR-a fusion protein, displaces co-repressors of differentiation
Indications: AML (APL)
F: PO
Toxicities:
APL differentiation syndrome (retinoic acid-APL syndrome): fever, weight gain, pulmonary infiltrates, pleural or pericardial effusion, multi-organ failure
Leukocytosis (opposite of myelosuppression)
Hepatotoxicity
Cardiovascular toxicity (edema, thrombosis)
GI toxicity (nausea, vomiting, diarrhea, hemorrhage)
Arsenic trioxide
Trisenox
DIFFERENTIATION AGENT
MOA: promotes the degradation of PML-RAR-a fusion protein, generates free radicals and inhibits angiogenesis
Indications: AML (APL)
F: IV
Toxicities:
APL differentiation syndrome
Leukocytosis
Cardiotoxicity (QT prolongation)- due to metal moiety
Electrolyte imbalance
GI toxicity (nausea, vomiting, diarrhea)
Bortezomib
Velcade
Misc Agent
MOA: 26S proteosome inhibitor, causing inactivation of NF-kB
Indications: multiple myeloma, lymphoma
F: IV or SQ
Toxicities:
Peripheral neuropathy
Myelosuppression
GI toxicity (nausea, vomiting, diarrhea, constipation)
Misc: dose reduction for hepatic impairment
Thalidomide
Thalomid
Misc Agent
MOA: (unclear) G1 arrest, apoptosis, inhibits cell adhesion, decreases angiogenesis, increases NK cell activity
Indications: multiple myeloma
F:PO
Toxicities:
Severe birth defect, teratogen
Myelosuppression
Deep vein thrombosis and pulmonary embolism
neurotoxicity (peripheral neuropathy , sedation, seizure)
GI toxicity (constipation, nausea)
Lenalidomide
Revlimid
Misc agent
MOA: (unclear) G1 arrest, apoptosis, inhibits cell adhesion, decreases angiogenesis, increases NK cell activity
Indications: multiple myeloma
F: PO
Toxicities:
Myelosuppression-serious
Other toxicities less severe than thalidomide
L-asparaginase
Elpsar
Misc agent
MOA: deprives tumor cells that relay on exogenous L-asparagine, inhibits protein synthesis and causes cell death
Indications: ALL
F: IV or IM
Toxicities:
Hypersensitivity reactions
Hepatotoxicity
Inhibition of protein synthesis, leading to:
hyperglycemia (dec insulin)
clotting abnormalities (dec clotting factors)
hypertrigleridemia (dec lipoprotein), pancreatitis
Bleomycin
Blenoxane
Misc agent
MOA: cause single- and double-stranded DNA breaks
Indications: lymphoma, melanoma, testicular
F: IV, IM, or SQ
Toxicities:
Pulmonary fibrosis- dose dependant/limiting
Cutaneous reactions (hyperpigmentation, erythema, ulceration)
Hypersensitivity reactions
Hepatotoxicity
Misc: dose reduction for renal impairment, Maximum cumulative lifetime dose: 400 unit***
Abarelix
Plenaxis
ANTI-HORMONAL AGENT
Anastrazole
Arimidex
ANTI-HORMONAL AGENT
Bicalutamide
Casodex
ANTI-HORMONAL AGENT
Exemestane
Aromasin
ANTI-HORMONAL AGENT
Flutamide
Eulexin
ANTI-HORMONAL AGENT
Fulvestrant
Faslodex
ANTI-HORMONAL AGENT
Selective estrogen-receptor downregulator (SERD), pure anti-estrogen
MOA: inhibit ER dimerization and increase its degradation
Indications: ER-positive breast cancer, postmenopausal
F: IM
Toxicities:
Hot flashes, nausea, vomiting, headache
Misc: effective in tamoxifen-resistant cells
Goserelin
Zoladex
ANTI-HORMONAL AGENT
LHRH Agonist
MOA: Suppression of ovarian due to decreased levels of LH and FSH with subsequent decrease in estrogen in women
Letrozole
Femara
ANTI-HORMONAL AGENT
Leuprolide acetate
Lupron Depot, Viadur, Eligard
ANTI-HORMONAL AGENT
Megestrol Acetate
Megace
ANTI-HORMONAL AGENT
Nilutamide
Nilandron
ANTI-HORMONAL AGENT
Raloxifene
Evista
ANTI-HORMONAL AGENT
Selective Estrogen Receptor Modulators (SERMs)
MOA: downregulate ER (anti-estrogenic in breast cells, estrogenic in uterus (endometric cells))
Indications: ER+ breast cancer
F: po
Toxicities:
Increased risk for stroke in patients with coronary heart disease
Increased risk for thromboembolic disease
Hot flashes, edema, vaginal bleeding, vomiting
Misc: extensive first-pass effect
Tamoxifen
Nolvadex
ANTI-HORMONAL AGENT
Selective Estrogen Receptor Modulators (SERMs)
MOA: downregulate ER (anti-estrogenic in breast cells, estrogenic in uterus (endometric cells))
Indications: ER+ breast cancer
F: po
Toxicities:
Increased risk for uterine (endometric) cancer
Thromboembolic events (stroke, pulmonary)
Occular toxicity
Hepatotoxicity
Decreased bone mineral density in premanopausal patients
Hot flashes, edema, vaginal bleeding, nausea
Toremifene
Fareston
ANTI-HORMONAL AGENT
Selective Estrogen Receptor Modulators (SERMs)
MOA: downregulate ER (anti-estrogenic in breast cells, estrogenic in uterus (endometric cells))
Indications: ER+ breast cancer (postmenopausal)
F: po
Toxicities:
Hot flashes, nausea, vaginal discharge
Degarelix
Firmagon
ANTI-HORMONAL AGENT
Alemtuzumab
Campath
MONOCLONAL ANTIBODY
Bevacizumab
Avastin
MONOCLONAL ANTIBODY
Cetuximab
Erbitux
MONOCLONAL ANTIBODY
Ipilimumab
Yervoy
MONOCLONAL ANTIBODY
Pantimumab
Vectibix
MONOCLONAL ANTIBODY
Rituximab
Rituxan
MONOCLONAL ANTIBODY
Trastuzumab
Herceptin
MONOCLONAL ANTIBODY
Brentuximab Vedotin
Adcetris
MONOCLONAL ANTIBODY
Ofatumumab
Arzerra
MONOCLONAL ANTIBODY